IL-1 and allergy

Allergology International

Volumn 59, Issue 2, 2010, Pages 125-135

  Nambu, Aya ^a,b   Nakae, Susumu ^a,b  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Allergy; Asthma; Dermatitis; IL 1

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1ALPHA ANTIBODY; INTERLEUKIN 1BETA ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; INTERLEUKIN 1 RECEPTOR;

ALLERGIC RHINITIS; ALLERGY; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CONTACT ALLERGY; DELAYED HYPERSENSITIVITY; HOST RESISTANCE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MOUSE; T LYMPHOCYTE;

ANIMALS; ANTI-ALLERGIC AGENTS; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-1; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-1; T-LYMPHOCYTES;

EID: 77954551711     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.10-RAI-0190     Document Type: Review

References (146)

1. Dinarello CA Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-52.
2. Dinarello CA Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
3. Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol 2001;167:90-7.
4. Nakae S, Asano M, Horai R, Iwakura Y. Interleukin-1b, but not interleukin-1a, is required for T-cell-dependent antibody production. Immunology 2001;104:402-9.
5. Nakae S, Komiyama Y, Yokoyama H et al. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int Immunol 2003;15:483-90.
6. Shibuya K, Robinson D, Zonin F et al. IL-1a and TNF-a are required for IL-12-induced development of Th1 cells producing high levels of IFN-g in BALB/c but not C57BL/6 mice. J Immunol 1998;160:1708-16.
7. Von Stebut E, Ehrchen JM, Belkaid Y et al. Interleukin-1a promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/cmice. J Exp Med 2003;198:191-9.
8. Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007;81:1258-68.
9. Werman A, Werman-Venkert R, White R et al. The precursor form of IL-1a is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 2004; 101: 2434-9.
10. Kurt-Jones EA, Hamberg S, Ohara J, Paul WE, Abbas AK. Heterogeneity of helper/inducer T lymphocytes. I. Lym-phokine production and lymphokine responsiveness. J Exp Med 1987;166:1774-87.
11. Manetti R, Barak V, Piccinni MP et al. Interleukin-1 favours the in vitro development of type 2 T helper (Th2) human T-cell clones. Res Immunol 1994;145:93-100.
12. Huber M, Beuscher HU, Rohwer P, Kurrle R, Rollinghoff M, Lohoff M. Costimulation via TCR and IL-1 receptor reveals a novel IL-1a-mediated autocrine pathway of Th2 cell proliferation. J Immunol 1998;160:4242-7.
13. Ben-Sasson SZ, Hu-Li J, Quiel J et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA 2009; 106: 7119-24.
14. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008;226:57-79.
15. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226:10-8.
16. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27: 519-50.
17. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20-38.
18. Horai R, Asano M, Sudo K et al. Production of mice deficient in genes for interleukin (IL)-1a, IL-1b, IL-1a/b, and IL-1 receptor antagonist shows that IL-1b is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998;187:1463-75.
19. Zheng H, Fletcher D, Kozak W et al. Resistance to fever induction and impaired acute-phase response in interleukin-1b-deficient mice. Immunity 1995;3:9-19.
20. Shornick LP, De Togni P, Mariathasan S et al. Mice deficient in IL-1b manifest impaired contact hypersensitivity to trinitrochlorobenzone. J Exp Med 1996;183:1427-36.
21. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of in-terleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A 1996;93: 11008-13.
22. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-12.
23. Iizasa H, Yoneyama H, Mukaida N et al. Exacerbation of granuloma formation in IL-1 receptor antagonist-deficient mice with impaired dendritic cell maturation associated with Th2 cytokineproduction. J Immunol 2005;174:3273-80.
24. Labow M, Shuster D, Zetterstrom M et al. Absence of IL-1 signaling and reduced inflammatory response in IL-1 type I receptor-deficient mice. J Immunol 1997;159:2452-61.
25. Glaccum MB, Stocking KL, Charrier K et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 1997;159:3364-71.
26. Cullinan EB, Kwee L, Nunes P et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998;161:5614-20.
27. Li P, Allen H, Banerjee S et al. Mice deficient in IL-1b-converting enzyme are defective in production of mature IL-1b and resistant to endotoxic shock. Cell 1995;80:401-11
28. Kuida K, Lippke JA, Ku G et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995;267:2000-3.
29. Yamanaka K, Tanaka M, Tsutsui H et al. Skin-specific caspase-1-transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J Immunol 2000;165:997-1003.
30. Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998;19:37-44.
31. Cher DJ, Mosmann TR Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 1987;138:3688-94.
32. Fong TA, Mosmann TR. The role of IFN-g in delayed-type hypersensitivity mediated byTh1 clones. J Immunol 1989; 143:2887-93.
33. Bouley DM, Kanangat S, Wire W, Rouse BT. Characteri-zation of herpes simplex virus type-1 infection and her-petic stromal keratitis development in IFN-gamma knockout mice. J Immunol 1995;155:3964-71.
34. Molesworth-Kenyon SJ, Oakes JE, Lausch RN. A novel role for neutrophils as a source of T cell-recruiting chemokines IP-10 and Mig during the DTH response to HSV-1 antigen. J Leukoc Biol2005;77:552-9.
35. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon g gene-disrupted mice. J Exp Med 1993;178:2243-7.
36. Akahira-Azuma M, Szczepanik M, Tsuji RF et al. Early delayed-type hypersensitivity eosinophil infiltrates depend on T helper 2 cytokines and interferon-g via CXCR3 chemokines. Immunology 2004;111:306-17.
37. Gao D, Kasten-Jolly J, Lawrence DA. The paradoxical effects of lead in interferon-g knockout BALB/cmice. Toxi-col Sci 2006;89:444-53.
38. Feuerer M, Eulenburg K, Loddenkemper C, Hamann A, Huehn J. Self-limitation of Th1-mediated inflammation by IFN-g. J Immunol 2006;176:2857-63.
39. Irmler IM, Gajda M, Brauer R. Exacerbation of antigen-induced arthritis in IFN-g-deficient mice as a result of unrestricted IL-17 response. J Immunol 2007;179:6228-36.
40. Nakae S, Komiyama Y, Nambu A. et al. Antigen-specificT cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002;17:375-87.
41. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, De Sauvage FJ. Compromised humoral and delayed-type hy-persensitivity responses in IL-23-deficient mice. J Immunol 2004;172:2827-33.
42. Ishigame H, Kakuta S, Nagai T et al. Differential roles of interleukin-17A and -17F in host defense against mucoepi-thelial bacterial infection and allergic responses. Immunity 2009;30:108-19.
43. Umemura M, Yahagi A, Hamada S et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 2007;178:3786-96.
44. Chu CQ, Field M, Andrew E, Haskard D, Feldmann M, Maini RN. Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Clin Exp Immunol 1992;90:522-9.
45. Sugisaki K, Dannenberg AM Jr, Abe Y et al. Nonspecific and immune-specific up-regulation of cytokines in rabbit dermal tuberculous (BCG) lesions. J Leukoc Biol 1998;63: 440-50.
46. Juffermans NP, Verbon A, van Deventer SJ, van Deute-kom H, Speelman P, van der Poll T. Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis. Am J Respir Crit Care Med 1998; 157:1328-31.
47. Wilkinson RJ, Patel P, Llewelyn M et al. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1b on tuberculosis. J Exp Med1999; 189:1863-74.
48. Igarashi K, Mitsuyama M, Muramori K, Tsukada H, No-moto K. Interleukin-1-induced promotion of T-cell differentiation in mice immunized with killed Listeria monocy-togenes. Infect Immun 1990;58:3973-9.
49. Tumpey TM, Fenton R, Molesworth-Kenyon S, Oakes JE, Lausch RN. Role for macrophage inflammatory protein 2 (MIP-2), MIP-1a, and interleukin1a in the delayed-type hypersensitivity response to viral antigen. J Virol 2002;76: 8050-7.
50. Nambu A, Nakae S, Iwakura Y. IL-1b, but not IL-1a, is required for antigen-specific T cell activation and the induction of local inflammation in the delayed-type hypersensi-tivity responses. Int Immunol 2006;18:701-12.
51. Brook FA, Gardner RL. The origin and efficient derivation of embryonic stem cells in the mouse. Proc Natl Acad Sci USA 1997;94:5709-12.
52. Auerbach W, Dunmore JH, Fairchild-Huntress V et al. Es-tablishment and chimera analysis of 129/SvEv- and C57BL/6-derived mouse embryonic stem cell lines. Biotechniques 2000;29:1024-8, 1030, 1032.
53. Ware CB, Siverts LA, Nelson AM, Morton JF, Ladiges WC. Utility of a C57BL/6 ES line versus 129 ES lines for targeted mutations in mice. Transgenic Res 2003;12:743-6.
54. McVicar DW, Winkler-Pickett R, Taylor LS et al. Aberrant DAP12 signaling in the 129 strain of mice: implications for the analysis of genetargeted mice. J Immunol 2002;169: 1721-8.
55. Crawley JN, Belknap JK, Collins A et al. Behavioral phe-notypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 1997;132:107-24.
56. Linder CC. The influence of genetic background on spontaneous and genetically engineered mouse models of complex diseases. Lab Anim (NY) 2001;30:34-9.
57. Carlucci F, Cortes-Hernandez J, Fossati-Jimack L et al. Genetic dissection of spontaneous autoimmunity driven by 129-derived chromosome 1 Loci when expressed on C57BL/6mice. J Immunol 2007;178:2352-60.
58. Chabas D, Baranzini SE, Mitchell D et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-5.
59. Blom T, Franzen A, Heinegard D, Holmdahl R. Comment on The influence of the proinflammatory cytokine, osteo-pontin, on autoimmune demyelinating disease. Science 2003;299:1845; author reply 1845.
60. Maeda N, Johnson L, Kim S, Hagaman J, Friedman M, Reddick R. Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds. Atherosclerosis 2007;195: 75-82.
61. McCutcheon JE, Fisher AS, Guzdar E, Wood SA, Light-man SL, Hunt SP. Genetic background influences the behavioural and molecular consequences of neurokinin-1 receptor knockout. Eur J Neurosci 2008;27:683-90.
62. Kimber I, Dearman RJ. Allergic contact dermatitis: the cellular effectors. Contact Dermatitis 2002;46:1-5.
63. Bour H, Peyron E, Gaucherand M et al. Major histocom-patibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur J Immunol 1995;25:3006-10.
64. Bouloc A, Cavani A, Katz SI. Contact hypersensitivity in MHC class II-deficient mice depends on CD8 T lymphocytes primed by immunostimulating Langerhans cells. J Invest Dermatol 1998; 111:44-9.
65. Saulnier M, Huang S, Aguet M, Ryffel B. Role of interferon-g in contact hypersensitivity assessed in interferon-g receptor-deficient mice. Toxicology 1995; 102: 301-12.
66. Reeve VE, Bosnic M, Nishimura N. Interferon-g is involved in photoimmunoprotection by UVA (320-400 nm) radiationinmice. J Invest Dermatol 1999;112:945-50.
67. Dhabhar FS, Satoskar AR, Bluethmann H, David JR, McEwen BS. Stress-induced enhancement of skin immune function: A role for g interferon. Proc Natl Acad Sci USA 2000;97:2846-51.
68. Nakae S, Komiyama Y, Narumi S, et al. IL-1-induced tumor necrosis factor-a elicits inflammatory cell infiltration in the skin by inducing IFN-g-inducible protein 10 in the elicitation phase of the contact hypersensitivity response. Int Immunol 2003;15:251-60.
69. Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int 2008;57:121-34.
70. Berg DJ, Leach MW, Kuhn R et al. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J Exp Med 1995;182:99-108.
71. Traidl C, Jugert F, Krieg T, Merk H, Hunzelmann N. Inhibition of allergic contact dermatitis to DNCB but not to oxazolone in interleukin-4-deficient mice. J Invest Dermatol 1999;112:476-82.
72. Dieli F, Sireci G, Scire E, Salerno A, Bellavia A. Impaired contact hypersensitivity to trinitrochlorobenzene in interleukin-4-deficient mice. Immunology 1999;98:71-9.
73. Weigmann B, Schwing J, Huber H et al. Diminished contact hypersensitivity response in IL-4 deficient mice at a late phase of the elicitation reaction. Scand J Immunol 1997;45:308-14.
74. Enk AH, Katz SI. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992;89:1398-402.
75. Bigler CF, Norris DA, Weston WL, Arend WP. Interleukin-1 receptor antagonist production by human keratinocytes. J Invest Dermatol 1992;98:38-44.
76. Rambukkana A, Pistoor FH, Bos JD, Kapsenberg ML, Das PK. Effects of contact allergens on human Langer-hans cells in skin organ culture: migration, modulation of cell surface molecules, and early expression of interleukin-1b protein. Lab Invest 1996;74:422-36.
77. La E, Fischer SM. Transcriptional regulation of intracellular IL-1 receptor antagonist gene by IL-1a in primary mouse keratinocytes. J Immunol 2001;166:6149-55.
78. Kermani F, Flint MS, Hotchkiss SA. Induction and localization of cutaneous interleukin-1b mRNA during contact sensitization. Toxicol Appl Pharmacol 2000;169:231-7.
79. Jakob T, Udey MC. Regulation of E-cadherin-mediated adhesion in Langerhans cell-like dendritic cells by inflammatory mediators that mobilize Langerhans cells in vivo. J Immunol 1998;160:4067-73.
80. Enk AH, Angeloni VL, Udey MC, Katz SI. An essential role for Langerhans cell-derived IL-1b in the initiation of primary immune responses in skin. J Immunol 1993; 150: 3698-704.
81. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. JExp Med 1995; 181:2237-47.
82. Cumberbatch M, Dearman RJ, Kimber I. Langerhans cells require signals from both tumour necrosis factor-a and interleukin-1b for migration. Immunology 1997;92: 388-95.
83. Cumberbatch M, Dearman RJ, Groves RW, Antonopoulos C, Kimber I. Differential regulation of epidermal langer-hans cell migration by interleukins (IL)-1a and IL-1b during irritant- and allergen-induced cutaneous immune responses. Toxicol Appl Pharmacol 2002;182:126-35.
84. Wang B, Zhuang L, Fujisawa H et al. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J Immunol 1999;162:277-83.
85. Nakae S, Naruse-Nakajima C, Sudo K, Horai R, Asano M, Iwakura Y. IL-1a, but not IL-1b, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivity. Int Immunol 2001; 13: 1471-8.
86. Shornick LP, Bisarya AK, Chaplin DD. IL-1b is essential for langerhans cell activation and antigen delivery to the lymph nodes during contact sensitization: evidence for a dermal source of IL-1b. Cell Immunol 2001;211:105-12.
87. Dekaris I, Zhu SN, Dana MR. TNF-a regulates corneal Langerhans cell migration. J Immunol 1999;162:4235-9.
88. Faherty DA, Claudy V, Plocinski JM et al. Failure of IL-1receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo. J Immunol 1992;148:766-71.
89. Rauschmayr T, Groves RW, Kupper TS. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci USA 1997;94:5814-9.
90. Kondo S, Pastore S, Fujisawa H et al. Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol 1995;105:334-8.
91. Nagai H, Ueda Y, Ochi T, et al. Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6mice. Br J Pharmacol 2000;129: 299-306.
92. Kupper TS, Ballard DW, Chua AO et al. Human keratino-cytes contain mRNA indistinguishable from monocyte in-terleukin 1a and b mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to inter-leukin 1. J Exp Med 1986;164:2095-100.
93. Heufler C, Topar G, Koch F et al. Cytokine gene expression in murine epidermal cell suspensions: interleukin 1b and macrophage inflammatory protein 1a are selectively expressed in Langerhans cells but are differentially regu-latedinculture. J Exp Med 1992;176:1221-6.
94. Enk AH, Katz SI. Early events in the induction phase of contact sensitivity. J Invest Dermatol 1992;99:39S-41.
95. Rasanen L, Lehto M, Reunala T, Jansen C, Leinikki P. Decreased monocyte production of interleukin-1 and impaired lymphocyte proliferation in atopic dermatitis. Arch Dermatol Res 1987;279:215-8.
96. Kapp A, Kirnbauer R, Luger TA, Schopf E. Altered production of immuno-modulating cytokines in patients with atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:97-9.
97. Jakob T, Neuber K, Ring J. Decreased monocyte interleukin-1b production in atopic eczema. Br J Dermatol 1995;132:384-90.
98. Higashi N, Gesser B, Kawana S, Thestrup-Pedersen K. Expression of IL-18 mRNA and secretion of IL-18 are reduced in monocytes from patients with atopic dermatitis. J Allergy Clin Immunol 2001;108:607-14. 99.
99. Thestrup-Pedersen K, Larsen CS, Kristensen M, Zachar-iae C. Interleukin-1 release from peripheral blood mono-cytes and soluble interleukin-2 and CD8 receptors in serum from patients with atopic dermatitis. Acta Derm Ve-nereol 1990;70:395-9.
100. Bochner BS, Charlesworth EN, Lichtenstein LM et al. Interleukin-1 is released at sites of human cutaneous allergic reactions. J Allergy Clin Immunol 1990;86:830-9.
101. Junghans V, Gutgesell C, Jung T, Neumann C. Epidermal cytokines IL-1b, TNF-a, and IL-12 in patients with atopic dermatitis: response to application of house dust mite antigens. J Invest Dermatol 1998;111:1184-8.
102. Dowd PM, Camp RD, Greaves MW. Human recombinant interleukin-1a is proinflammatory in normal human skin. Skin Pharmacol 1988;1:30-7.
103. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001; 117: 977-83.
104. Chen L, Overbergh L, Mathieu C, Chan LS. The development of atopic dermatitis is independent of Immuno-globulin E up-regulation in the K14-IL-4 SKH1 transgenic mouse model. Clin Exp Allergy 2008;38:1367-80.
105. Groves RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. Proc Natl Acad Sci U S A 1995;92:11874-8.
106. Groves RW, Rauschmayr T, Nakamura K, Sarkar S, Williams IR, Kupper TS. Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease. J Clin Invest 1996;98:336-44.
107. Konishi H, Tsutsui H, Murakami T et al. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci USA 2002;99:11340-5.
108. Oghiso Y, Kubota Y. Enhanced interleukin 1 production by alveolar macrophages and increase in Ia-positive lung cells in silica-exposed rats. Microbiol Immunol 1986;30: 1189-98.
109. Becker S, Devlin RB, Haskill JS. Differential production of tumor necrosis factor, macrophage colony stimulating factor, and interleukin 1 by human alveolar macrophages. J Leukoc Biol 1989;45:353-61.
110. Stassen M, Arnold M, Hultner L, et al. Murinebone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol 2000; 164:5549-55.
111. Hultner L, Kolsch S, Stassen M et al. In activated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9. J Immunol 2000;164: 5556-63.
112. Kandere-Grzybowska K, Letourneau R, Kempuraj D et al. IL-1 induces vesicular secretion of IL-6 without degranula-tion from human mast cells. J Immunol 2003;171:4830-6.
113. Lee SA, Fitzgerald SM, Huang SK et al. Molecular regulation of interleukin-13 and monocyte chemoattractant protein-1 expression in human mast cells by interleukin-1 beta. Am J Respir Cell Mol Biol 2004;31:283-91.
114. Ho LH, Ohno T, Oboki K et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FceRI signals. J Leukoc Biol 2007;82:1481-90.
115. Iikura M, Suto H, Kajiwara N et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-8.
116. Karjalainen J, Hulkkonen J, Pessi T et al. The IL1A genotype associates with atopy in nonasthmatic adults. J Allergy Clin Immunol 2002;110:429-34.
117. Karjalainen J, Nieminen MM, Aromaa A, Klaukka T, Hurme M. The IL-1b genotype carries asthma susceptibil-ityonlyinmen. J Allergy Clin Immunol 2002;109:514-6.
118. Adjers K, Pessi T, Karjalainen J, Huhtala H, Hurme M. Epistatic effect of IL1A and IL4RA genes on the risk of atopy. J Allergy Clin Immunol 2004;113:445-7.
119. Zeyrek D, Demir E, Alpman A, Ozkinay F, Gulen F, Tanac R. Association of interleukin-1b and interleukin-1 receptor antagonist gene polymorphisms in Turkish children with atopic asthma. Allergy Asthma Proc 2008;29: 468-74.
120. Mahajan B, Vijayan VK, Agarwal MK, Bansal SK. Serum interleukin-1b as a marker for differentiation of asthma and chronic obstructive pulmonary disease. Biomarkers 2008;13:713-27.
121. Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN. Expression of interleukin-1b (IL-1b) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 1996;154:1061-6.
122. Reynolds AM, Holmes MD, Scicchitano R. Interleukin-1b and tumour necrosis factor-a increase microvascular leakage in the guinea pig trachea. Respirology 2002;7:23-8.
123. Wilmott RW, Kitzmiller JA, Fiedler MA, Stark JM. Generation of a transgenic mouse with lung-specific overex-pression of the human interleukin-1 receptor antagonist protein. Am J Respir Cell Mol Biol 1998;18:429-34.
124. Tamaoki J, Yamawaki I, Takeyama K, Chiyotani A, Yamauchi F, Konno K. Interleukin-1b inhibits airway smooth muscle contraction via epithelium-dependent mechanism. Am J Respir Crit Care Med 1994;149:134-7.
125. Tsukagoshi H, Sun J, Kwon O, Barnes PJ, Chung KF. Role of neutral endopeptidase in bronchial hyperrespon-siveness to bradykinin induced by IL-1b. J Appl Physiol 1995;78:921-7.
126. Okada S, Inoue H, Yamauchi K et al. Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. J Allergy Clin Immunol 1995;95:1236-45.
127. Lloyd CM, Gonzalo JA, Coyle AJ, Gutierrez-Ramos JC. Mouse models of allergic airway disease. Adv Immunol 2001;77:263-95.
128. Moffatt JD. What targets have knockouts revealed in asthma? Pharmacol Ther 2005;107:343-57.
129. Schmitz N, Kurrer M, Kopf M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 2003;33:991-1000.
130. Broide DH, Campbell K, Gifford T, Sriramarao P. Inhibition of eosinophilic inflammation in allergen-challenged, IL-1 receptor type 1-deficient mice is associated with reduced eosinophil rolling and adhesion on vascular endo-thelium. Blood 2000;95:263-9.
131. Zosky GR, Larcombe AN, White OJ et al. Airway hyperresponsiveness is associated with activated CD4+ T cells in the airways. Am J Physiol Lung Cell Mol Physiol 2009;297: L373-9.
132. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1b induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107:1529-36.
133. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1b causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 2005;32:311-8.
134. Park JW, Taube C, Swasey C et al. Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone. Am J Respir Cell Mol Biol 2004;30: 830-6.
135. Johnson VJ, Yucesoy B, Luster MI. Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 2005;116:851-8.
136. Nakae S, Suto H, Berry GJ, Galli SJ. Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice. Blood 2007; 109:3640-8.
137. Subramanian N, Bray MA. Interleukin 1 releases hista-mine from human basophils and mast cells in vitro. J Immunol 1987;138:271-5.
138. Theodorou V, Fioramonti J, Bueno L. Recombinant interleukin-1 receptor antagonist protein prevents sensiti-zation and intestinal anaphylaxis in guinea pigs. Life Sci 1993;53:733-8.
139. Theodorou V, Fioramonti J, Junien JL, Bueno L. Anaphy-lactic colonic hypersecretion in cow's milk sensitized guinea-pigs depends upon release of interleukin-1, prostaglandins and mast cell degranulation. Aliment Pharmacol Ther 1994;8:301-7.
140. Joki-Erkkila VP, Karjalainen J, Hulkkonen J et al. Allergic rhinitis and polymorphisms of the interleukin 1 gene complex. Ann AllergyAsthma Immunol 2003;91:275-9.
141. Kenney JS, Baker C, Welch MR, Altman LC. Synthesis of interleukin-1a, interleukin-6, and interleukin-8 by cultured human nasal epithelial cells. J Allergy Clin Immunol 1994; 93:1060-7.
142. Gosset P, Malaquin F, Delneste Y et al. Interleukin-6 and interleukin-1a production is associated with antigen-induced late nasal response. J Allergy Clin Immunol 1993; 92:878-90.
143. Sim TC, Grant JA, Hilsmeier KA, Fukuda Y, Alam R. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am J Respir Crit Care Med1994;149:339-44.
144. Zhang HQ, Sun Y, Xu F. Therapeutic effects of interleukin-1 receptor antagonist on allergic rhinitis of guinea pig. Acta Pharmacol Sin 2003;24:251-5.
145. Asano-Kato N, Fukagawa K, Okada N et al. TGF-b1, IL-1b, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. Exp Eye Res 2005;80:555-60.
146. Keane-Myers AM, Miyazaki D, Liu G, Dekaris I, Ono S, Dana MR. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 1999;40:3041-6.